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Gene therapies for recessive genetic diseases may
provoke unwanted immune responses against the
introduced gene product because patients, especially
those with null mutation of a certain protein, have no
tolerance for the protein of interest.This study used des-
moglein 3 knockout (Dsg3^/^) mice as a disease model
for a genetic defect in DSG3, to investigate whether
nonviral gene therapy induces an immune response
against Dsg3 and whether the reaction against Dsg3
can be prevented. When mouse Dsg3 cDNA was in-
jected in the skin of Dsg3^/^ mice, 50% of treated
Dsg3^/^ mice developed anti-Dsg3 IgG, which can bind
native Dsg3 in vivo. To prevent this response, we used
an anti-CD40L monoclonal antibody, MR1, which
blocks the costimulatory interaction between CD40
and CD40L. To evaluate the e¡ect of MR1, we grafted
Dsg3þ/þ skin on Dsg3^/^ mice, to mimic stable gene
transfer of Dsg3. After skin grafting, all the recipient
Dsg3^/^ mice were treated with either MR1 (n¼ 8) or
control hamster IgG (n¼ 8). All of the control IgG-trea-
ted mice developed circulating anti-Dsg3 IgG about
2 wk after grafting, and IgG deposition was observed
on the surfaces of keratinocytes in the grafted Dsg3þ/þ
skin. Such anti-Dsg3 IgG production was signi¢cantly
prevented, however, when the recipient mice were trea-
ted with MR1.These ¢ndings suggested that gene thera-
pies for recessive diseases may provoke an immune
response against the transgene product, and that the
CD40^CD40L interaction might be a reasonable target
for e¡ective prevention of such undesirable immune re-
sponses, leading, in turn, to a successful gene therapy.
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S
kin is an attractive target for gene therapy, because it is
readily accessible for gene transfer, gene expression is
easily observed, and the skin can be removed when an
unexpected side-e¡ect occurs (Vogel, 1993; Greenhalgh
et al, 1994; Hengge et al, 1995; 1996). As in other organs,
the genetic correction of recessive genodermatoses is of great
potential value, as only palliative therapies are at present available
(Khavari, 1998; 2000; Uitto and Pulkkinen, 2000). Therefore,
attempts to develop gene therapies for forms of epidermolysis
bullosa (Dellambra et al, 1998; Vailly et al, 1998; Seitz et al, 1999;
Chen et al, 2000), X-linked ichthyosis (Jensen et al, 1993; Freiberg
et al, 1997), lamellar ichthyosis (Choate et al, 1996), and xeroderma
pigmentosum (Zeng et al, 1998) have been reported. In these
studies, expression of the intended genes was successful and the
impaired protein functions were corrected. Several hurdles
remain to be cleared before practical gene therapy can be applied,
however. One such problem is how to achieve long-term expres-
sion of the introduced gene at therapeutic levels. This matter has
attracted great interest and has been investigated intensively. By
contrast, little attention has been paid to the immune reaction
that might be provoked against the introduced gene products.
As skin is a primary immunologic barrier against foreign sub-
jects and contains many antigen-presenting cells (dendritic cells)
(Tuting et al, 1998; Larregina and Falo, 2000), the immune
response against a transgene product, and the prevention of this
response, is a priority issue in gene therapy that is targeted on
skin. This problem becomes particularly important when gene
therapy is applied to correct a recessive genetic disease caused by
null mutation. In these patients, the immune system has never
encountered the missing protein. Accordingly, there is no toler-
ance of what would be a novel protein in such patients. Conse-
quently, any gene product introduced to correct a genetic defect
might be recognized as a foreign antigen, which would inevitably
result in an unwanted immune response against the introduced
gene product (Khavari, 1998; 2000). In contrast, patients with
missense mutations may still express endogenous gene product
that serves as self-protein to establish self-tolerance although its
function is altered. Despite the signi¢cance of this phenomenon,
such immune responses in the skin, or in other organs, have not
been satisfactorily studied. Several investigators have reported im-
mune reactions against transgene products. As gene delivery was
performed using viral vectors, however, it transpires that most of
these documented reactions were against the transgene vehicles
(Dai et al, 1995; Tripathy et al, 1996; Yang et al, 1996; Ilan et al,
1997; Morral et al, 1997; Stein et al, 1999; 2000). This means that
Reprint requests to: Masayuki Amagai, M.D., Ph.D., Department of
Dermatology, Keio University School of Medicine, 35 Shinanomachi,
Shinjyuku-ku,Tokyo 160-8582, Japan; Email: amagai@sc.itc.keio.ac.jp
Abbreviation: Dsg, desmoglein.
Manuscript received July 17, 2002; revised October 13, 2002; accepted for
publication November 5, 2002
0022-202X/03/$15.00  Copyrightr 2003 by The Society for Investigative Dermatology, Inc.
610
the immune response elicited against a transgene product has not
yet been evaluated. In addition, only a few studies have dealt
with the issue of immune provocation against a corrected self-
antigen in a gene therapy model of recessive disease (Ilan et al,
1997; Stein et al, 2000). Therefore, an adequate animal model and
immune assay are required in order to further evaluate and pre-
vent such undesirable immune responses.
Desmoglein 3 (Dsg3) is an epithelial type transmembrane des-
mosomal component that belongs to the cadherin gene super-
family; it has been identi¢ed as the autoimmune target of
pemphigus vulgaris (Amagai et al, 1991; 1994). In 1997, the Dsg3
knockout (Dsg3^/^) mouse was generated by genetic disruption
of DSG3 (Koch et al, 1997). The adult mouse develops crusted
erosions on traumatized skin, telogen-speci¢c hair loss, and
weight loss due to decreased food intake as a result of painful ero-
sions on the mucous membranes that are manifestations of Dsg3
dysfunction. Recently, we intensively investigated the gross and
histopathologic phenotype of Dsg3^/^ mice (Ohyama et al,
2002) in order to characterize their pathophysiology. In addition,
we have developed an enzyme-linked immunosorbent assay
(ELISA) using recombinant mouse Dsg3, which should prove to
be a valuable tool for detecting circulating anti-Dsg3 IgG in mice
(Amagai et al, 2000).
In this study, using the Dsg3^/^ mouse as a disease model for a
genetic defect inDSG3, we investigated whether an undesirable im-
mune response against the transgene product of Dsg3 was actually
provoked after naked DNA injection of Dsg3 cDNA in Dsg3^/^
mice. Then, we showed that blockading the CD40^CD40L inter-
action prevented this undesirable immune response.
MATERIALS AND METHODS
Mice Dsg3^/^ mice were obtained by mating a male Dsg3^/^ mouse
and female Dsg3þ/^ mice (Koch et al, 1997; Amagai et al, 2000). These
mice have a mixed genetic background of 129/SV (H-2b) and C57BL/6 J
(H-2b). The C57BL/6 J mice used as skin graft donors were purchased
from Japan Clea (Tokyo, Japan). All mice studies were approved by the
animal ethics review board of Keio University, Japan.
DNA constructs The plasmid pcDNA-mouse Dsg3 (mDsg3) was
constructed by subcloning mDsg3 cDNA between the EcoR1 and Sph1
sites of pcDNA1 containing the CMV promoter (Invitrogen, Carlsbad,
CA). Dr. Jouni Uitto (Je¡erson Medical College, Philadelphia, PA)
generously provided the cDNA.
Naked DNA injection Materials for naked DNA injection were
prepared and the injection was performed essentially as previously
described (Hengge et al, 1995; 1996). The puri¢ed plasmid DNA was
diluted to the indicated concentrations with phosphate-bu¡ered saline.
Injections into the super¢cial dermis of the footpad or shaved trunk skin
were performed using syringes with ultra-¢ne 29G needles (U-100, Japan
Becton Dickinson, Tokyo, Japan). The injected volume was 20^50 ml,
depending on the site. Ten Dsg3^/^ mice were divided into four groups
to undergo gene therapy with pcDNA-mDsg3 naked DNA injection, at
doses of 50^200 mg per mouse per injection, and at injection frequencies
that ranged from once every 2 wk to twice per week. The indicated
quantity of DNAwas dissolved in 100ml of phosphate-bu¡ered saline per
injection for each individual mouse. Two C57BL/6 J (Dsg3þ/þ ) mice
were treated with 200 mg per mouse every 2 wk as controls. Serum was
collected at weekly intervals for further analysis. To determine whether
anti-Dsg3 IgG binds to the transgene product, pcDNA^mDsg3 (1 mg per
ml) was injected into the footpads of a Dsg3^/^ mouse that had produced
anti-Dsg3 IgG after naked DNA injection of pcDNA^mDsg3. Biopsy
specimens from the footpads were taken 12 h after injection and frozen
sections were prepared. These were incubated with 100-fold diluted
£uorescein isothiocyanate anti-mouse IgG antibody for 1 h, washed, and
embedded for microscopic investigation.
Dsg3 expression assay To evaluate the potential of the constructed
DNA to express Dsg3 in epidermis, plasmid solution of either pcDNA^
mDsg3 or pcDNA1 (5 or 10 mg per ml for pcDNA^mDsg3, 10 mg per ml
for pcDNA1) was injected into one or two sites per footpad (six to eight
sites per mouse) in Dsg3^/^ mice (n¼ 2 for each concentration of DNA).
Skin biopsies were performed 18 h after injection. Samples were embedded
in OCT compound (Sakura Finetechnical, Tokyo, Japan) and cryostat
sections of these samples were prepared for direct immuno£uorescence
study. Sections were ¢rst incubated for 1 h with anti-mouse Dsg3
monoclonal antibody, AK9 (Tsunoda et al, manuscript in preparation).
Sections were then incubated for 1 h with 100-fold diluted £uorescein
isothiocyanate rabbit anti-mouse IgG antibody (Zymed Laboratories, San
Francisco, CA). All these sections were examined using £uorescence
microscopy (Eclipse E800, Nikon,Tokyo, Japan).
ELISA The production of anti-Dsg3 and anti-Dsg1 IgG was evaluated by
ELISA, using recombinant mouse Dsg3 and Dsg1, as previously reported
(Ohyama et al, 2002). Brie£y, diluted sera (500-fold for sera of mice treated
with naked DNA injection of Dgs3, 1000-fold for sera of Dsg3^/^ mice
with Dsg3þ/þ skin graft) were incubated for 1 h on ELISA plates coated
with 2.5 mg per ml mouse rDsg3, or rDsg1, expressing the entire
extracellular domains using a baculovirus expression system (Amagai et al,
2000). After washing, the plates were incubated with 5000-fold diluted
peroxidase-labeled goat anti-mouse IgG (Zymed Laboratories) for 1 h.
After the second wash, color was developed using a solution containing
equal amounts of tetramethylbenzidine and hydrogen peroxide (Medical
Biological Laboratories, Nagano, Japan) for 30 min, and stopped by
adding 100 ml of 4 N H2SO4. The OD was measured at 450 nm using a
microplate reader (Bio-Rad Laboratories, Hercules, CA).We calculated the
mean and standard deviation for this ELISA using OD values of control
sera from 12 normal mice. Based on the meanþ 3SD, we set the cut-o¡
values for de¢nite positive reactivity as 0.090 for Dsg3 IgG and 0.067 for
Dsg1 IgG. Sera were tested at least twice for Dsg3 ELISA and once for
Dsg1 ELISA.
Grafting Dsg3þ/þ skin onto Dsg3^/^ mice For the skin graft
procedure, 8 8 mm pieces of dorsal skin were removed from sacri¢ced
6- to 12-wk-old wild-type C57BL/6 J mice and placed in sterile saline.
Seven 8- to 12-wk-old Dsg3^/^ mice, which have a mixed genetic
background of 129/SV and C57BL/6 J, were carefully anesthetized with
dimethyl ether and the dorsal skin was replaced with the skin graft. The
graft was attached with nylon sutures. After topical application of
ointment containing gentamicin sulfate (Schering-Plough, Osaka, Japan),
the surgical site was dressed with gauze and an elastic bandage for 7^10 d.
Typically, successful adaptation was obtained and grafts were maintained at
the surgical site for about 3 wk. Then, grafts began to necrotize and were
spontaneously removed within 4 wk probably due to allo-reaction. Then a
second piece of Dsg3þ/þ skin was grafted onto the Dsg3^/^ mice to
evaluate the in vivo reaction of anti-Dsg3 IgG. Serum samples from these
mice with grafts were collected once a week. Sera diluted 1 : 1000 were
analyzed for anti-Dsg1 and anti-Dsg3 IgG with ELISA using recombinant
mouse Dsg1 and Dsg3.
MR1/hamster IgG treatment Hamster anti-mouse CD40L mono-
clonal antibody MR1was prepared according to the protocol described in
the original report (Noelle et al, 1992). Hybridomas producing MR1were
injected intraperitoneally into hamsters and the collected ascites was
puri¢ed by ion-exchange high performance liquid chromatography to
obtain MR1. The Dsg3^/^ mice with skin grafts were injected
intraperitoneally with either MR1 (n¼ 8) or control hamster IgG (n¼ 8)
(Cappel Product, Aurora, OH).The dose of MR1was determined based on
previous reports (Durie et al, 1993;Yang et al, 1996; Stein et al, 1999; 2000) as
well as our pilot study. In our pilot study 125 mg to 1 mg per mouse were
tested at various schedules, but 125^250 mg per mouse showed only partial
suppression.Therefore, expecting substantial suppression, we used 1mg per
mouse at day 0 and 0.5 mg per mouse at days 2, 4, 7, 14, 21, and 28. Serum
samples from these mice were collected once a week and analyzed with
ELISA using mouse rDsg3 and mouse rDsg1, as described above. To
evaluate whether intercellular deposition of IgG in the epidermis of the
skin graft occurred, E2 6 mm biopsy samples were taken from the
second skin grafts, about 1 wk after grafting, and examined for IgG
deposition by direct immuno£uorescence. Seven grafts from eight
MR1-treated mice and ¢ve grafts from eight control-IgG-treated mice
were investigated in this study.
RESULTS
Development of anti-Dsg3 IgG in Dsg3^/^ mice after naked
DNA injection of Dsg3 cDNA We used Dsg3^/^ mice as a
model for recessive genodermatosis. To correct the defect in
Dsg3 expression, we introduced Dsg3 cDNA by naked DNA
injection. The proper expression of Dsg3 in the epidermis was
con¢rmed by staining skin sections from the injection site for
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Dsg3. Distinct positive staining for Dsg3 was observed on the
surfaces of keratinocytes at the sites injected with 5^10 mg per ml
pcDNAmDsg3 (Fig 1a), whereas no such cell surface
staining for Dsg3 was observed at the sites injected with
pcDNA1 (Fig 1b). We then determined whether Dsg3^/^
mice develop anti-Dsg3 IgG after naked DNA injection of
pcDNAmDsg3. Dsg3^/^ mice were injected with various
amounts of pcDNAmDsg3 in various schedules (Table I), and
serial serum samples were evaluated by mouse Dsg3 as well as
mouse Dsg1 ELISA. Each mouse in the three groups of Dsg3^/^
mice injected with 50 mg pcDNAmDsg3 per mouse twice per
week (n¼ 2), or 100 mg per mouse once (n¼ 4) or twice (n¼ 2)
developed anti-Dsg3 IgG at day 32. Although the anti-Dsg3 IgG
level detected in these groups was relatively low, more distinct
anti-Dsg3 IgG production was observed in two out of two
Dsg3^/^ mice injected with 200 mg per mouse every 2 wk
(Fig 2a). Therefore, anti-Dsg3 IgG production was observed
altogether in ¢ve of the 10 mice examined when 500 mg per
mouse or more total naked DNAwas injected. The sera of these
mice with anti-Dsg3 IgG showed no apparent reactivity against
mouse Dsg1 at a mean OD value of 0.04670.011 (n¼ 5). In
contrast to Dsg3^/^ mice, no anti-Dsg3 IgG production was
observed in two wild-type mice (C57BL/6 J) injected with the
same amount of DNA (Fig 2a).
Next, we determined whether the anti-Dsg3 IgG produced
after the naked DNA injection binds to the exogenous Dsg3
expressed by naked DNA injection in Dsg3^/^ mice. Biopsies
were taken at the injection sites (footpad) of Dsg3^/^ mice
producing anti-Dsg3 IgG after naked DNA injection, and in vivo
IgG deposition was examined by direct immuno£uorescence
(Fig 2b). Obvious in vivo IgG deposition was noticed on
keratinocyte cell surfaces in six out of 36 biopsy sections. This
indicated that the anti-Dsg3 IgG produced after the naked DNA
injection of Dsg3 cDNA could bind to gene therapy transgene
products in vivo.
Blockade of CD40L prevented anti-Dsg3 IgG production in
Dsg3^/^ mice with Dsg3þ/þ skin graft Achieving stable
gene expression of the transgene is one of the ultimate goals of
gene therapy. To mimic the state of stable gene expression, we
grafted skin from wild-type Dsg3þ/þmice onto Dsg3^/^
mice instead of injecting Dsg3 cDNA. In this model,
production of anti-Dsg3 IgG was observed in all of the mice
tested 2 wk after skin grafting, and the titers increased thereafter
(Fig 3, n¼ 7). The sera of these mice did not show any cross-
Figure1. Dsg3 expressed on keratinocyte cell surfaces following
naked DNA injection. Positive staining for Dsg3 was observed on the
surfaces of keratinocytes at the site of pcDNAmDsg3 injection into a
footpad of a Dsg3^/^ mouse (a), but not at the site of control DNA injec-
tion (b). Scale bar: 50 mm.
Table I. Production of anti-Dsg3 IgG in Dsg3^/^ mice after naked DNA injection of pcDNAmDsg3
Dose per injection per mouse n Schedule Mice with anti-Dsg3 IgG Total DNA injecteda Time requiredb
50 mg 2 Twice per week 1 500 mg 32 d
100 mg 4 Once per week 1 500 mg 32 d
100 mg 2 Twice per week 1 1000 mg 32 d
200 mg 2 Once every 2 wk 2 600/800 mg 35/56 d
aTotal DNA injected when anti-Dsg3 IgG production was observed.
bTime required for development of anti-Dsg3 IgG.
Figure 2. Anti-Dsg3 IgG production in Dsg3^/^ mice after naked
DNA injection. (a) Anti-Dsg3 IgG production was measured by ELISA
over time after naked DNA injection. Dsg3^/^ mice injected with
pcDNAmDsg3 (200 mg per mouse, every 2 wk) developed anti-Dsg3
IgG. No such IgG elevation was observed in Dsg3þ/þ control mice, how-
ever. (b) In vivo deposition of IgG in the epidermis was observed (arrow) at
the site of pcDNAmDsg3 injection in a Dsg3^/^ mouse that was produ-
cing anti-Dsg3 IgG. Scale bar: 50 mm.
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reactivity with Dsg1. As the Dsg3^/^ mice used in this study had
a mixed genetic background of 129/SVand C57BL/6 J, the grafted
Dsg3þ/þ skin of the C57BL/6 J mice was rejected about 3 wk
after grafting. This earlier production of anti-Dsg3 IgG observed
in these Dsg3þ/þ skin grafted Dsg3^/^ mice, compared to that
in mice with naked DNA injection, might be partly explained by
an adjuvant e¡ect accompanying rejection of the skin graft.
We used these skin-grafted Dsg3^/^ mice as a model for stable
gene transfer of Dsg3 in Dsg3^/^ mice and examined whether
blockade of the CD40L^CD40 interaction by anti-CD40L
monoclonal antibody, MR1, could prevent unwanted anti-Dsg3
IgG production in Dsg3^/^ mice. Dsg3^/^ mice with Dsg3þ/
þ skin were treated with either MR1 (n¼ 8) or control hamster
IgG (n¼ 8) at days 0, 2, 4, 7, 14, 21, and 28 following the skin
graft. Serial serum samples from these mice were analyzed with
mouse Dsg3 ELISA (Table II, Fig 4). The production of anti-
Dsg3 IgG was detected in seven of eight mice treated with
control IgG at day 14 and in eight of eight mice at day 21 and
was maintained as long as observed until day 42. No apparent
cross-reactivity against mouse Dsg1 was detected in those mice
(mean OD value¼ 0.01970.006). In contrast, none of the mice
injected with MR1 showed apparent anti-Dsg3 IgG production
at day 14. Although some anti-Dsg3 IgG production was noted
after day 28 in the mice injected with MR1, the titers were
signi¢cantly lower than in mice injected with control IgG. The
di¡erence in the titers in the two groups was statistically
signi¢cant (p¼ 0.0005, Mann^Whitney analysis at day 28).
Furthermore, direct immuno£uorescence of the skin grafts on
MR1/control IgG-treated mice was used to look for IgG
deposition on the keratinocyte cell surfaces (Fig 5a). Distinct
IgG deposition on the surfaces of keratinocytes in the epidermis
and telogen hair follicles was observed in the skin grafts on the
control IgG-treated mice (Fig 5b, n¼ 5), whereas no apparent
in vivo IgG deposition was observed in the skin grafts of the
MR1-treated mice (Fig 5c, n¼ 7). These ¢ndings indicate that
the Dsg3þ/þ skin graft induced anti-Dsg3 IgG production in
Dsg3^/^ mice in an antigen-speci¢c way, and that the blockade
of CD40L by MR1 e⁄ciently prevented the unwanted anti-
Dsg3 IgG production in this model.
DISCUSSION
In this study, we employed Dsg3^/^ mice as an animal model of
recessive genodermatosis. To simulate gene delivery, we used
naked DNA injection in order to evaluate the immune reaction
against a transgene product in the absence of a vehicle, such as
viral vectors. In this study, Dsg3 was successfully expressed in
the epidermis of Dsg3^/^ mice with naked DNA injection of
pcDNAmDsg3. Some of the injected Dsg3^/^ mice developed
anti-Dsg3 IgG, which showed no cross-reactivity with Dsg1. In
contrast, such IgG production was not observed in Dsg3þ/
þ control mice. Furthermore, the resulting anti-Dsg3 IgG bound
in vivo to the Dsg3 expressed by naked DNA injection, as IgG
deposition was observed on the surfaces of keratinocytes at the
sites of DNA injection. Although it is not clear whether induced
anti-Dsg3 IgG blocks the function of Dsg3, these ¢ndings sug-
gested that the immune response provoked by gene therapy
might impair the function of the introduced gene product itself.
Therefore, the establishment of an adequate way to prevent such
an immune reaction would be bene¢cial to successful gene ther-
apy for recessive genetic diseases with null mutation, where the
absence of tolerance against the introduced gene product is likely
to elicit an unfavorable immune response.
Several approaches have been proposed as a means of overcom-
ing the immune response against a transgene product or vector in
gene therapy models using viral vectors. Such strategies include
inducing central tolerance by intrathymic inoculation of adeno-
viral antigens (Ilan et al, 1996), inducing oral tolerance by feeding
adenoviral antigens (Ilan et al, 1997), utilizing immunosuppressive
agents, such as cyclosporine or cyclophosphamide (Dai et al, 1995),
and blocking costimulatory signals between CD28B7 (Kay
et al, 1995) or CD40CD40L (Yang et al, 1996; Stein et al, 1999;
2000). CD40 is a glycoprotein member of the nerve growth
factor receptor/tumor necrosis factor receptor family, which
is expressed mainly on B cells and antigen-presenting cells,
whereas its counterpart, CD40L, is transiently expressed on acti-
vated CD4þT helper cells (Datta and Kalled, 1997). The
CD40CD40L pathway, which upregulates B7 on antigen-pre-
senting cells (Ranheim and Kipps, 1993; Roy et al, 1995), is one
of the critical costimulatory signals for T cell activation, B cell
proliferation, and immunoglobulin secretion (Datta and Kalled,
1997;Yamada and Sayegh, 2002). The blockade of this interaction
with anti-CD40L antibody has been used to inhibit the immune
response against gene therapy transgene products in lung, liver, or
brain (Yang et al, 1996; Stein et al, 1999; 2000). Such blockade of
this pathway, however, has never been performed in gene therapy
for the skin. Considering the central role of antigen-presenting
cells in provoking the immune response in DNA immunization
(Tuting et al, 1998), and the functional expression of CD40 on hu-
man epidermal Langerhans cells (Peguet-Navarro et al, 1995) and
keratinocytes (Denfeld et al, 1996), blockade of the CD40^CD40L
interaction with a monoclonal antibody against CD40L seems to
be an e¡ective way to prevent an undesirable immune response in
cutaneous gene therapy. Indeed, in the Dsg3þ/þ skin graft
model, anti-Dsg3 IgG production was successfully suppressed in
Figure 3. Dsg3þ/þ skin grafting onto Dsg3^/^ mice elicited anti-
Dsg3 IgG production. (a) A Dsg3^/^ mouse with a Dsg3þ/þ skin
graft, at day 10 after the skin graft. Patchy hair loss and erosions are the
normal characteristics of Dsg3^/^ mice. Dsg3^/^ mice with the Dsg3þ/þ
skin graft (n¼ 7) produced anti-Dsg3 IgG within 2 wk after the graft, and
this showed no cross-reactivity against Dsg1, as con¢rmed by ELISA (b).
Error bars indicate the mean7SEM.
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MR1-treated mice, whereas all of the control IgG-treated mice
developed the undesired IgG within 2^3 wk, and the titer of
IgG was maintained at high levels for more than 6 wk. Further-
more, no in vivo IgG deposition on keratinocyte surfaces was
observed in the epidermis of skin grafts on the mice treated with
MR1. The advantages of anti-CD40L therapy are that it does not
require prior knowledge of the structure of the autoantigen and
that its e¡ect is relatively speci¢c because the CD40L molecule is
expressed mainly on activated T cells (Datta and Kalled, 1997).
Unlike other immunosuppressive agents, such as corticosteroids
or cyclosporine, generalized immunosuppression was not observed
in previous murine studies of anti-CD40L antibody (Durie et al,
1993; 1994; Mohan et al, 1995; Early et al, 1996; Gerriset et al, 1996).
Although additional evidence is needed before it can be applied
in practice, the blockade of the CD40^CD40L interaction with
monoclonal antibody appears to be a valuable way to prevent an
unwanted immune response against a transgene product, a re-
sponse that may well be provoked in gene therapy.
Taking all these ¢ndings into consideration, we conclude that
an unwanted immune response against a desired gene product
may be provoked in gene therapy for recessive disease, and that
adequate prevention of such an unfavorable immune reaction is
required for the practical application of this promising therapy.
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Table II. Anti-Dsg3 IgG production (OD450) in MR1/control IgG treated Dsg3^/^ mice with Dsg3þ/þ skin graft
Time course (d)
Mouse 0 7 14 21 28 35 42
MR1-treated mice
# 1 0.014 0.011 0.009 0.002 0.017 0.003 ND
# 2 0.013 0.016 0.025 0.014 0.042 0.047 0.620
# 3 0.013 0.013 0.044 0.070 0.085 0.210 0.130
# 4 0.013 0.007 0.049 0.043 0.600 0.780 0.110
# 5 0.011 0.005 0.017 ND ND ND ND
# 6 0.010 0.014 0.014 0.014 0.140 0.450 0.590
# 7 0.010 0.005 0.002 0.027 0.017 0.049 ND
# 8 0.005 0.003 0.009 0.098 0.600 0.600 0.007
Meanþ SEM 0.011þ0.001 0.004þ 0.002 0.021þ0.006 0.038þ 0.012 0.210þ 0.094 0.310þ 0.11 0.290þ 0.130
Control IgG-treated mice
# 9 0.050 0.004 1.200 1.520 1.420 1.400 ND
# 10 0.015 0.015 0.580 0.970 0.430 0.700 1.310
# 11 0.014 0.012 0.530 1.060 1.300 1.300 1.300
# 12 0.008 0.006 0.330 1.300 2.140 2.360 1.210
# 13 0.006 0.014 1.160 0.790 0.570 0.600 1.860
# 14 0.006 0.007 1.160 1.750 1.760 1.980 0.990
# 15 0.008 0.005 0.920 1.300 1.380 1.610 ND
# 16 0.004 0.011 0.084 1.520 1.170 1.110 ND
Meanþ SEM 0.014þ 0.005 0.009þ 0.002 0.750þ 0.150 1.280þ 0.110 1.270þ 0.200 1.380þ 0.210 1.330þ 0.140
OD values above the cuto¡ values are in bold. ND indicates not determined.
Figure 4. MR1 e¡ectively suppressed the anti-Dsg3 IgG production
provoked by grafting Dsg3þ/þ skin on Dsg3^/^ mice. All of the
control IgG-treated mice developed anti-Dsg3 IgG about 2 wk after graft-
ing and this IgG production was maintained at high levels for more than 6
wk. This immune reaction was e¡ectively suppressed when recipient mice
were treated with MR1. Error bars indicate the mean7SEM. nMean was
obtained with ¢ve mice at day 42.
Figure 5. IgG deposition on the surfaces of keratinocytes in Dsg3þ/
þgrafts on Dsg3^/^ mice and its e⁄cient prevention with MR1.
Dsg3^/^ mice with Dsg3þ/þ skin grafts were treated with control ham-
ster IgG (a, left) or MR1 (a, right). IgG deposition on keratinocyte cell sur-
faces was detected in the grafts from control IgG-treated mice (b), whereas
this deposition was prevented in the grafts from MR1-treated mice (c).
Scale bars: 1 cm for (a); 50 mm for (b), (c).
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